Stocks of Atara Biotherapeutics Inc. (NASDAQ:ATRA) traded higher last session on Wall Street, up 7.28% to $2.21.
According to the data, Atara Biotherapeutics Inc. (NASDAQ:ATRA) has 9 analysts covering its stock. The consensus rating among analysts is ‘Overweight’. As we calculate the median target price by taking the range between a high of $31.00 and a low of $2.00, we find $20.00. Given the previous closing price of $2.06, this indicates a potential upside of 870.87 percent. ATRA stock price is now 17.88% away from the 50-day moving average and -32.65% away from the 200-day moving average. The market capitalization of the company currently stands at $188.18M.
A total of 2 analysts have issued a hold rating and 5 have given it a buy rating. Brokers who have rated the stock have averaged $16.27 as their price target over the next twelve months.
With the price target reduced from $8 to $3, Citigroup Downgraded its rating from Neutral to Sell for Atara Biotherapeutics Inc. (NASDAQ: ATRA).
In other news, Touchon Pascal, President and CEO sold 14,291 shares of the company’s stock on Jun 27. The stock was sold for $23,723 at an average price of $1.66. Upon completion of the transaction, the President and CEO now directly owns 706,671 shares in the company, valued at $1.56 million. An SEC document containing details of the transaction can be found on the SEC’s website. On May 16, President and CEO Touchon Pascal sold 29,766 shares of the business’s stock. A total of $60,633 was realized by selling the stock at an average price of $2.04. This leaves the insider owning 720,962 shares of the company worth $1.59 million. Insiders disposed of 157,543 shares of company stock worth roughly $0.35 million over the past 1 year. A total of 1.50% of the company’s stock is owned by insiders.
There have been several recent changes in the stakes of large investors in ATRA stock. A new stake in Atara Biotherapeutics Inc. shares was purchased by UBS ASSET MANAGEMENT AMERICAS INC during the first quarter worth $239,000. PROFUND ADVISORS LLC invested $231,000 in shares of ATRA during the first quarter. In the first quarter, HARBOR CAPITAL ADVISORS, INC. acquired a new stake in Atara Biotherapeutics Inc. valued at approximately $111,000. VANGUARD PERSONALIZED INDEXING MANAGEMENT, LLC acquired a new stake in ATRA for approximately $69,000. POINT72 ASSET MANAGEMENT, L.P. purchased a new stake in ATRA valued at around $60,000 in the second quarter.
During the past 12 months, Atara Biotherapeutics Inc. has had a low of $1.45 and a high of $5.94. As of last week, the company has a debt-to-equity ratio of 0.01, a current ratio of 3.30, and a quick ratio of 3.20. The fifty day moving average price for ATRA is $1.8778 and a two-hundred day moving average price translates $3.2724 for the stock.
The latest earnings results from Atara Biotherapeutics Inc. (NASDAQ: ATRA) was released for Mar, 2023. According to the Biotechnology Company, earnings per share came in at -$0.72, missing analysts’ expectations of -$0.39 by -0.33. This compares to -$0.87 EPS in the same period last year. The company reported revenue of $1.23 million for the quarter, compared to $7.31 million a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue fell -83.24 percent. For the current quarter, analysts expect ATRA to generate $3.77M in revenue.
